156 related articles for article (PubMed ID: 21153334)
1. Identification of new candidates as mucosal vaccine adjuvant in TNF family cytokines.
Kayamuro H; Yoshioka Y; Abe Y; Katayama K; Arita S; Nomura T; Yoshikawa T; Itoh N; Kamada H; Tsunoda S; Tsutsumi Y
Adv Exp Med Biol; 2011; 691():299-304. PubMed ID: 21153334
[No Abstract] [Full Text] [Related]
2. The use of a mutant TNF-alpha as a vaccine adjuvant for the induction of mucosal immune responses.
Kayamuro H; Abe Y; Yoshioka Y; Katayama K; Nomura T; Yoshida T; Yamashita K; Yoshikawa T; Kawai Y; Mayumi T; Hiroi T; Itoh N; Nagano K; Kamada H; Tsunoda S; Tsutsumi Y
Biomaterials; 2009 Oct; 30(29):5869-76. PubMed ID: 19646748
[TBL] [Abstract][Full Text] [Related]
3. Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines.
Patel GB; Zhou H; Ponce A; Chen W
Vaccine; 2007 Dec; 25(51):8622-36. PubMed ID: 17959279
[TBL] [Abstract][Full Text] [Related]
4. Stimulation of local antibody production: parenteral or mucosal vaccination?
Bouvet JP; Decroix N; Pamonsinlapatham P
Trends Immunol; 2002 Apr; 23(4):209-13. PubMed ID: 11923116
[TBL] [Abstract][Full Text] [Related]
5. Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa.
Cox E; Verdonck F; Vanrompay D; Goddeeris B
Vet Res; 2006; 37(3):511-39. PubMed ID: 16611561
[TBL] [Abstract][Full Text] [Related]
6. Protollin: a novel adjuvant for intranasal vaccines.
Jones T; Cyr S; Allard F; Bellerose N; Lowell GH; Burt DS
Vaccine; 2004 Sep; 22(27-28):3691-7. PubMed ID: 15315848
[TBL] [Abstract][Full Text] [Related]
7. Cell-penetrating peptide-linked polymers as carriers for mucosal vaccine delivery.
Sakuma S; Suita M; Inoue S; Marui Y; Nishida K; Masaoka Y; Kataoka M; Yamashita S; Nakajima N; Shinkai N; Yamauchi H; Hiwatari K; Tachikawa H; Kimura R; Uto T; Baba M
Mol Pharm; 2012 Oct; 9(10):2933-41. PubMed ID: 22953762
[TBL] [Abstract][Full Text] [Related]
8. Compound 48/80 acts as a potent mucosal adjuvant for vaccination against Streptococcus pneumoniae infection in young mice.
Zeng L; Liu Y; Wang H; Liao P; Song Z; Gao S; Wu Y; Zhang X; Yin Y; Xu W
Vaccine; 2015 Feb; 33(8):1008-16. PubMed ID: 25595867
[TBL] [Abstract][Full Text] [Related]
9. Induction of mucosal immunity through systemic immunization: Phantom or reality?
Su F; Patel GB; Hu S; Chen W
Hum Vaccin Immunother; 2016 Apr; 12(4):1070-9. PubMed ID: 26752023
[TBL] [Abstract][Full Text] [Related]
10. All things mucosal.
Thanavala Y; Lavelle E; Ogra P
Expert Rev Vaccines; 2009 Feb; 8(2):139-42. PubMed ID: 19196192
[TBL] [Abstract][Full Text] [Related]
11. Adoptive transfer of transgenic T cells to study mucosal adjuvants.
Pettini E; Ciabattini A; Pozzi G; Medaglini D
Methods; 2009 Dec; 49(4):340-5. PubMed ID: 19409994
[TBL] [Abstract][Full Text] [Related]
12. Mucosal vaccines: a paradigm shift in the development of mucosal adjuvants and delivery vehicles.
Srivastava A; Gowda DV; Madhunapantula SV; Shinde CG; Iyer M
APMIS; 2015 Apr; 123(4):275-88. PubMed ID: 25630573
[TBL] [Abstract][Full Text] [Related]
13. Mutant TNF-alpha, mTNF-K90R, is a novel candidate adjuvant for a mucosal vaccine against HIV.
Kayamuro H; Abe Y; Yoshioka Y; Katayama K; Yoshida T; Yamashita K; Yoshikawa T; Kawai Y; Mayumi T; Hiroi T; Itoh N; Nagano K; Kamada H; Tsunoda S; Tsutsumi Y
Pharmazie; 2010 Apr; 65(4):254-6. PubMed ID: 20432620
[TBL] [Abstract][Full Text] [Related]
14. TNF superfamily member, TL1A, is a potential mucosal vaccine adjuvant.
Kayamuro H; Yoshioka Y; Abe Y; Katayama K; Yoshida T; Yamashita K; Yoshikawa T; Hiroi T; Itoh N; Kawai Y; Mayumi T; Kamada H; Tsunoda S; Tsutsumi Y
Biochem Biophys Res Commun; 2009 Jul; 384(3):296-300. PubMed ID: 19406102
[TBL] [Abstract][Full Text] [Related]
15. Non-toxic Stx derivatives from Escherichia coli possess adjuvant activity for mucosal immunity.
Ohmura-Hoshino M; Yamamoto M; Yuki Y; Takeda Y; Kiyono H
Vaccine; 2004 Sep; 22(27-28):3751-61. PubMed ID: 15315856
[TBL] [Abstract][Full Text] [Related]
16. Defending the mucosa: adjuvant and carrier formulations for mucosal immunity.
Lawson LB; Norton EB; Clements JD
Curr Opin Immunol; 2011 Jun; 23(3):414-20. PubMed ID: 21511452
[TBL] [Abstract][Full Text] [Related]
17. Mucosal vaccines: Strategies and challenges.
Li M; Wang Y; Sun Y; Cui H; Zhu SJ; Qiu HJ
Immunol Lett; 2020 Jan; 217():116-125. PubMed ID: 31669546
[TBL] [Abstract][Full Text] [Related]
18. Inducing Mucosal IgA: A Challenge for Vaccine Adjuvants and Delivery Systems.
Boyaka PN
J Immunol; 2017 Jul; 199(1):9-16. PubMed ID: 28630108
[TBL] [Abstract][Full Text] [Related]
19. Recent progress in mucosal vaccine development: potential and limitations.
Lycke N
Nat Rev Immunol; 2012 Jul; 12(8):592-605. PubMed ID: 22828912
[TBL] [Abstract][Full Text] [Related]
20. Modes of Action for Mucosal Vaccine Adjuvants.
Aoshi T
Viral Immunol; 2017; 30(6):463-470. PubMed ID: 28436755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
